Ebastine in chronic spontaneous urticaria in higher doses

Indian Journal of Dermatology

Volumn 56, Issue 5, 2011, Pages 597-598

  Godse, Kiran ^a  

^a Shree Skin Centre   (India)

Author keywords

[No Author keywords available]

Indexed keywords

EBASTINE;

ADULT; BEDTIME DOSAGE; CHRONIC URTICARIA; CLINICAL ARTICLE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; HUMAN; LETTER; MALE; PRURITUS; SEDATION; SIDE EFFECT; TREATMENT OUTCOME;

EID: 81255203578     PISSN: 00195154     EISSN: 19983611     Source Type: Journal    
DOI: 10.4103/0019-5154.87168     Document Type: Letter

References (7)

1. Zuberbier T, Bindslev-Jensen C, Canonica W, Grattan CE, Greaves MW, Henz BM, et al. EAACI/GA2LEN/EDF guideline: Management of urticaria. Allergy 2006;61:321-31.
2. Hurst M, Spencer CM. Ebastine: An update of its use in allergic disorders. Drugs 2000;59:981-1006. (Pubitemid 30232331)
3. Sastre J. Ebastine in allergic rhinitis and chronic idiopathic urticaria. Allergy 2008;63:1-20.
4. Godse KV. Updosing of antihistamines to improve control of chronic urticaria. Indian J Dermatol Venereol Leprol 2010;76:61-2.
5. Frossard N, Benabdesselam O, Purohit A, Mounedji N, Pauli G. Activity of ebastine (10 and 20 mg) and cetirizine at 24 hours of a steady state treatment in the skin of healthy volunteers. Fundam Clin Pharmacol 2000;14:409-13.
6. Magerl M, Schmolke J, Metz M, Zuberbier T, Siebenhaar F, Maurer M. Prevention of signs and symptoms of dermographic urticaria by single-dose ebastine 20 mg. Clin Exp Dermatol 2009l;34: E137-40.
7. Gillen MS, Miller B, Chaikin P, Morganroth J. Effects of supratherapeutic doses of ebastine and terfenadine on the QT interval. Br J Clin Pharmacol 2001;52:201-4. (Pubitemid 32863080)